232 results about "Methamphetamine" patented technology

One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.

A method is disclosed for analyzing a biological sample by antibody profiling for identifying forensic samples or for detecting the presence of an analyte. In an illustrative embodiment of the invention, the analyte is a drug, such as marijuana, cocaine, methamphetamine, methyltestosterone, or mesterolone. The method involves attaching antigens to the surface of a solid support in a preselected pattern to form an array wherein the locations of the antigens are known; contacting the array with the biological sample such that a portion of antibodies in the sample reacts with and binds to antigens in the array, thereby forming immune complexes; washing away antibodies that do form immune complexes; and detecting the immune complexes, thereby forming an antibody profile. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source. Further, an assay, such as a test for illegal drug use, can be coupled to a test for identity such that the results of the assay can be positively correlated to the subject's identity.

The invention generally relates to monoclonal antibodies that recognize at least one compound from the group consisting of (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Generally speaking, the monoclonal antibodies do not recognize (−) methamphetamine, (−) amphetamine, or (−) MDMA.

The present invention is related to antibodies directed to various drugs of abuse and uses of such antibodies. In preferred embodiments, the drugs of abuse are amphetamine, methamphetamine, or phencyclidine (PCP). In particular, in accordance with the present invention, there are provided fully man monoclonal antibodies directed to drugs of abuse. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and / or complementarity determining regions (CDR's), specifically from FR1 through FR3 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Cognitive impairments are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an 1-amphetamine compound. In another embodiment, the method includes administering an 1-methamphetamine compound.

The invention relates generally to ephedrine or pseudoephedrine compositions containing biocompatible organoleptic (food flavoring) excipients that would prevent the illicit manufacture of methamphetamine from ephedrine or pseudoephedrine.

A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia / ischemia condition or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with a transient cerebral hypoxic and / or ischemic condition, or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, in addition to the continuous intravenous infusion dose, a bolus dose of methamphetamine is administered to the subject as soon as possible after onset of the condition or occurrence of the TBI event.

In an effort to control the production of illegal drugs such as methamphetamine, new statutes have placed restrictions on the sale of common cold remedies that contain pseudoephedrine and other precursors used in the production of these illegal drugs. Many common products, such as Sudafed® cold medicine, have been removed from store shelves and are now behind the counter at most pharmacies. These legal restrictions vary from state to state, but most restrict the amount of product that can be purchased by quantity and time. These legal restrictions also require creation of a customer log that often includes the customer's name, address, government-issued photo identification number and / or signature. Clearance of these restricted product sales and creation of the customer log are time consuming tasks that result in long lines during the winter season. The present invention is an automated process to speed up the authorization process and creation of the customer logs. The process can be applied to a single store or multiple stores. The invention also includes a clearance terminal especially adapted for this process.

A method for analyzing a biological sample by antibody profiling for identifying forensic samples or for detecting the presence of an analyte. In an embodiment of the invention, the analyte is a drug, such as marijuana, Cocaine (crystalline tropane alkaloid), methamphetamine, methyltestosterone, or mesterolone. The method comprises attaching antigens to a surface of a solid support in a preselected pattern to form an array wherein locations of the antigens are known; contacting the array with the biological sample such that a portion of antibodies in the sample reacts with and binds to the antigens in the array to form immune complexes; washing away antibodies that do form immune complexes; and detecting the immune complexes, to form an antibody profile. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source. Further, an assay, such as a test for illegal drug use, can be coupled to a test for identity such that the results of the assay can be positively correlated to the subject's identity.

The invention discloses preparation and an application of a fluorescent compound having a sensing function on methamphetamine and methamphetamine analogues and preparation and an application of a fluorescent sensing thin film, and belongs to the technical field of fluorescent compound preparation. The fluorescent compound contains a cholesterol fragment and a 3,4,9,10-perylenetetracarboxylic acid anhydride unit, the cholesterol fragment has the advantages of rigid skeleton, multiple chiral centers and strong van der Waals effect and the like, 3,4,9,10-perylenetetracarboxylic acid anhydride has high fluorescence quantum yield, good photochemistry stability and strong pi-pi stacking interaction, and the construction units make the prepared fluorescent compound have supramolecular characteristics and extremely rich assembly behaviors simultaneously. The prepared sensing thin film has the advantages of controllable micro-morphology, good stability and high sensitivity, and can be used repeatedly; through device formation and combining development with a dedicated fluorescence detection platform, the sensing thin film is expected to be used for a dedicated detector for super sensitive gas-phase detection of methamphetamine and the methamphetamine analogues, and provides a technical support for drug investigation detective works.

The present invention provides synthetic immunochemical haptens for the generation of antibodies that are designed to recognize the common molecular features of d-methamphetamine-like abused stimulants with insignificant cross-reactivity to endogenous substrates (e.g. dopamine) or over-the-counter medications (e.g. 1-methamphetamine, pseudoephedrine, phenylpropanolamine and ephedrine). These monoclonal antibodies and their antigen binding fragments are useful in treatment plans for recovering addicts, in emergency room settings for rapidly reversing a drug overdose, in protection of fetuses from drug-abusing pregnant mothers or in a psychiatric setting to reduce the exacerbation of psychotic disorders caused by stimulant drugs.

A method for analyzing a biological sample by antibody profiling for identifying forensic samples or for detecting the presence of an analyte. In an embodiment of the invention, the analyte is a drug, such as marijuana, Cocaine (crystalline tropane alkaloid), methamphetamine, methyltestosterone, or mesterolone. The method comprises attaching antigens to a surface of a solid support in a preselected pattern to form an array wherein locations of the antigens are known; contacting the array with the biological sample such that a portion of antibodies in the sample reacts with and binds to the antigens in the array to form immune complexes; washing away antibodies that do form immune complexes; and detecting the immune complexes, to form an antibody profile. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source. Further, an assay, such as a test for illegal drug use, can be coupled to a test for identity such that the results of the assay can be positively correlated to the subject's identity.

The invention belongs to the technical field of drug detection, and particularly relates to a method for detecting methamphetamine through surface enhanced Raman spectroscopy, which includes the following steps: step I, pretreating a to-be-detected sample, so as to form sample solution; step II, preparing gold sol or silver sol; step III, uniformly mixing the test sample solution obtained through the step I and the gold sol or the silver sol obtained through the step II, so as to form the to-be-detected sample that is on standing; step IV, enabling the mixed to-be-detected sample obtained through the step III to be dripped on a slide and naturally evaporated for Raman spectrometry, thereby obtaining the SERS spectrogram of the gold sol and the to-be-detected sample or the SERS spectrogram of the silver sol and the to-be-detected sample; and step V, comparing the SERS spectrogram of the to-be-detected sample with the standard SERS spectrogram of the methamphetamine, so as to determine whether the sample contains the methamphetamine. The method for detecting the methamphetamine is simple to operate and quick to detect, has low sample consumption and detection cost, and can be widely applied to the detection field of the drug.

The invention provides a methamphetamine aptamer, a detection kit and application thereof. Specifically, based on an ssDNA library with a special structure, the inventor adopts the SELEX (systematic evolution of ligands by exponential enrichment) technique to successfully screen the aptamer with high affinity and specificity to methamphetamine. The aptamer provided by the invention can be used for on-site fast and sensitive detection of methamphetamine.

The invention belongs to the technical field of analytical chemistry, and relates to a method for rapidly assaying four amphetamines (amphetamine, methamphetamine, methylene-dioxy-amphetamine and methylene-dioxy-methamphetamine), ketamine, pethidine and methadone in blood and urine. The method is high in sensitivity and specificity and wide in linear range, can be used for qualitatively and quantitatively assaying analytes of unknown concentrations in the blood and the urine, and is simple and rapid to operate; according to the method, processes of extracting, and drying by evaporating are not required, and characteristics that a judicial expertise task is urgent and has a high requirement on assaying time can be met; an assaying system, provided by the invention, provides a new technical platform for drug assaying, and is easy to popularize and apply.

Cyclic tetrapeptides that are kappa opioid receptor (KOR) antagonists can be used in therapeutic applications for treating, inhibiting, and / or preventing drug addiction, drug use, or drug seeking behavior in a subject. This can include subjects that have a history of drug addiction. The drug can be selected from cocaine, alcohol, amphetamines, methamphetamines, nicotine, opiate, or combinations thereof. These cyclic tetrapeptides can also be useful for treating, inhibiting, and / or preventing stress-induced drug seeking behavior.

The invention generally relates to monoclonal antibodies that recognize at least one compound from the group consisting of (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Generally speaking, the monoclonal antibodies do not recognize (−) methamphetamine, (−) amphetamine, or (−) MDMA.

Methods and compositions for stabilizing methamphetamine laboratories, such as by mitigating their explosive potential.

The invention discloses a hapten and a complete antigen which are used for methamphetamine detection and antibody preparation. The invention also discloses an anti-methamphetamine monoclonal antibody prepared from the complete antigen, and a colloidal gold marked methamphetamine monoclonal antibody immunoassay plate, which are used for detecting the methamphetamine in pharmaceutical products and human specimens of urine samples and the like. Compared with chromatographic processes of HPLC and the like, the immunoassay plate is simple and portable and is easy to carry, can perform field detection, and needs no expensive devices. By using the immunoassay plate to detect the methamphetamine, the entire test can be finished in 3 to 5 minutes, the detection sensitivity can reach 300 ng, and the immunoassay plate has no cross-reactions with 60 common medicaments and poisons, in particular ephedrine and pseudoephedrine.

Compositions are disclosed. One embodiment of a composition comprises a first antibody having an affinity for an antigen and a second antibody having an affinity for the first antibody, wherein at least one antibody is conjugated to a marker, and wherein the antigen is not present in the composition. Further disclosed are methods of using compositions according to the invention for analyzing a biological sample by antibody profiling for identifying forensic samples or detecting the presence of an analyte. In embodiments of the invention, the analyte is a drug, such as marijuana, cocaine, methamphetamine, methyltestosterone, or mesterolone. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source. Further, an assay, such as a test for illegal drug use, may be coupled to a test for identity such that the results of the assay may be positively correlated to the subject's identity.

Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylenedioxy-ethylamphetamine (MDEA) and 4-hydroxy-3-methoxy-methamphetamine (HMMA). The method comprises providing in combination in a medium (i) a sample suspected of containing the compound and (ii) an antibody raised against a compound of Formula I that comprises a protein. The medium is examined for the presence a complex comprising the compound and the antibody where the presence of such as complex indicates the presence of the compound in the sample. In one aspect of the above embodiment, the combination further comprises a label conjugate of the compound Formula I.

The invention provides an optical probe based on a gold nanoparticle efficient assembly structure, and a preparation method and an application of the optical probe. Firstly, a high-load treelike mesoporous silicon ball / gold nanoparticle assembly is prepared by utilizing a sulfydryl-metal affinity effect in an organic phase; n-octyltrimethoxysilane / methanol / ammonia water serves as a hydrolysis system; silylation modification of a hydrophobic assembly is realized; the ultra-high load capacity of a treelike mesoporous silicon ball carrier to gold nanoparticles in a modification process is ensured; microspheres with stable properties and excellent performances are prepared through hydrolytic condensation of organosilane and growth process of Stober; and the microspheres are applied to an immunochromatographic test strip after being further carboxylated and functionalized by using an anti-methamphetamine, so that methamphetamine can be detected rapidly, specifically, accurately and sensitively within 15 minutes.

Mild cognitive impairment and Alzheimer's disease are treated with an amphetamine compound. In one embodiment, the method includes administering an 1-amphetamine compound. In another embodiment, the method includes administering an 1-methamphetamine compound.

Methods for the chiral separation and quantitative determination of the d- and l-enantiomers for amphetamine and methamphetamine in bodily fluids and tissues are provided. The method comprises providing a bodily fluid or tissue sample from a subject, extracting target analyte(s) from the sample, followed by eluting on a liquid chromatography column comprising a chiral stationary phase to yield an eluent, which is then analyzed for the presence of the analytes using a mass analyzer.

The invention relates to an application of a lead compound namely L-corydalmine (L-CDL) of isoquinoline compounds on treating diseases related with addiction. The diseases comprise drug addiction (heroin, opium, methyl amphetamine, morphine, marihuana, cocaine, and the like), nicotine addiction, and alcohol addiction, and also comprise novel drug addiction (stimulant type novel drugs) and brain damage caused by novel drugs.

The invention generally relates to hapten compounds comprising either (+) methamphetamine or (+) amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+) methamphetamine, (+) amphetamine, or (+) MDMA.

The invention belongs to the technical field of drug detection and judicial identification, and in particular relates to the detection of seven abused drugs amphetamine, methamphetamine, methylenedioxyamphetamine, methylenedioxy The method for extracting and measuring methamphetamine, ketamine, pethidine and methadone uses methanol as a dispersant and a protein precipitation solvent, uses dichloromethane as an extraction solvent, and forms a microemulsion system of a three-solvent system in an aqueous solution of pH 13, With the assistance of ultrasound, it is further emulsified for liquid-liquid microextraction, and the extraction process does not need to evaporate the extraction solvent; this method has high enrichment multiple and recovery rate, simple and fast operation, high sensitivity, strong specificity, wide linear range and It has the advantages of low cost and environmental friendliness, and can meet the characteristics of urgent judicial appraisal tasks and high requirements for detection time. The detection system of the invention provides a new technical platform for drug detection.